Fusion proteins binding to VEGF and angiopoietin

1. An isolated nucleic acid molecule encoding a fusion polypeptide capable of synchronously binding VEGF polypeptide and angiopoietin polypeptide comprising a nucleotide sequence encoding a Tie2 component and a nucleotide sequence encoding VEGFR component, wherein the combined nucleotide sequences encode DAAP#1 having SEQ ID NO:2.

2. A nucleic acid vector which comprises the nucleic acid molecule of claim 1 .

3. An expression vector comprising a nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is operatively linked to an expression control sequence.

4. An isolated host-vector system for the production of said fusion polypeptide which comprises the expression vector of claim 3 , in a suitable host cell.

5. The isolated host-vector system of claim 4 , wherein the suitable host cell is a bacterial cell, yeast cell, insect cell, or mammalian cell.

6. The fusion polypeptide encoded by the isolated nucleic acid molecule of claim 1 .

7. A composition capable of synchronously binding VEGF and angiopoietin molecule to form a nonfunctional complex comprising a multimer of the fusion polypeptide of claim 6 , and a pharmaceutically acceptable carrier and/or diluent thereof.

8. The composition of claim 7 , wherein the multimer is a dimer.

9. A method of producing said fusion polypeptide which comprises growing cells of the host-vector system of claim 4 , under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced.

10. The fusion polypeptide encoded by the nucleic acid sequence according to claim 1 , which has been modified by acetylation or pegylation.

11. A method of decreasing or inhibiting plasma leakage in a mammal comprising administering to a mammal in need thereof an effective amount of the fusion polypeptide of claim 6 .

12. The method of claim 11 , wherein the mammal is a human.

13. A method of attenuating or inhibiting blood vessel growth in a mammal comprising administering to the mammal in need thereof an effective amount of the fusion polypeptide of claim 6 .

14. A method of attenuating or inhibiting VEGF receptor ligand and Tie2 ligand activities in a mammal comprising administering to the mammal an effective amount of the fusion polypeptide of claim 6 .

15. A method of attenuating or inhibiting tumor growth in a mammal, comprising administering to a subject in need thereof a therapeutically effective amount of the fusion polypeptide of claim 6 .

16. A method of attenuating or inhibiting ascites formation in a human comprising administering to a subject in need thereof a therapeutically effective amount of the fusion polypeptide of claim 6 .

17. The method of claim 16 , wherein the ascites is associated with ovarian cancer.